|
ShareHope Medicine Co., Ltd. is a healthcare logistics and services provider established in 2003. The company operates through five main business segments: health management and operations, medical personnel dispatch, pharmaceutical and medical supply distribution, medical equipment leasing, and remote health care. Its business units include the Pharmaceutical Distribution Department, Specialty Services Department, and Health Management Department. The company develops integrated medical logistics services and has launched the Hermes medical smart voice system in partnership with Yang-Ming Chiao Tung University. It also operates the Minsheng Medical Precision Big Health Ecosystem and has made strategic investments in international digital pharmacy ventures, such as Arincare in Thailand. Summarised from the company's own disclosures |
Industry Medical Distribution | Homepage share-hope.com |
| Sector Healthcare | IR page — | |
|
Tags
medical logistics, pharmaceutical distribution, medical personnel dispatch, medical equipment leasing, remote health care, health management, smart voice systems, digital pharmacy, Hermes, Arincare, Minsheng Medical Precision Big Health Ecosystem
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | NT$ 2.381B |
| Market cap (USD) | $ 72.272M |
| P/E | 11.69 |
| PEG | — |
| P/BV | 0.71 |
| P/S | 0.52 |
| P/OCF | 8.93 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 4.0% |
| ROI | 4.1% |
| ROIC | 3.7% |
| Profit margin | 3.3% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | -21.6% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | 0% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.358B | 4.326B | 3.873B | 4.137B | 3.85B | 4.099B | 3.124B | 3.057B | 2.617B | 2.33B | 2.135B | 1.969B | 1.865B | 1.833B | 1.721B | 1.573B |
| Net profit | 141.727M | 200.097M | 124.557M | 293.946M | 232.663M | 247.712M | 195.052M | 145.852M | 124.367M | 123.364M | 216.664M | 106.255M | 89.139M | 73.258M | 49.942M | 100.243M |
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 23.35 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/S | 0.74 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial information published on MOPS, newest first, subjects as filed in Chinese, guarantee and loan balance notices and routine equipment purchases included. The link opens the company's material information on MOPS. Press releases from the company's own website, newest first.

最新消息
家族企業交棒難在哪?大成、志聖、敏盛接班人分享心法
2026第24屆遠見高峰會(以下簡稱「2026遠見高峰會」)於14日登場,首日下午的第五場專題論壇「大交棒時代 繼承者的多重挑戰」,由 《遠見雜誌》副社長李建興擔任主持人,聚焦在台灣家族企業的傳承與創新。三位與談人除了暢談接班路上的艱辛歷程,更從自身出發,分享自己的寶貴經驗,包括如何在接班之後大刀闊斧地轉型,帶領企業迎向AI時代,迎戰半導體供應鏈革命與醫療產業資本化浪潮。
首先,李建興引用台灣董事學會發布的《華人家族企業關鍵報告2025》,指出近十年來台灣家族企業市值占比從64%大幅下滑至32%,十年間直接腰斬;2023年更出現家族企業與台股大盤的「死亡交叉」,象徵台灣家族企業正式走入結構性衰退期。
他認為,台灣正站在一個歷史性的企業傳承十字路口,尤其台灣上市櫃公司逾七成是家族企業,創立時間已逾30年,因此未來十年將是台灣企業傳承最關鍵的時期。如何全面重新建構企業組織文化、推動數位轉型與跨國布局,才是企業真正能永續經營的關鍵。
楊弘仁:參考美國先例,敏盛串起全台醫療生態系 敏盛醫療體系執行長楊弘仁,在1998年返台接班,帶領公司從地區型醫院,搖身一變成為一間在全台有上千據點,橫跨醫療、健康管理與生技研發的醫療體系,也是台灣首間以醫院為本的上市公司。 談及集團版圖歷程,楊弘仁強調,父親是非常厲害的創業家,將敏盛醫療從一間只有17個病床的外科診所,擴張到數個據點。
「爸!你已經夠厲害了!但美國還有更厲害的,要不要試試看!」楊弘仁回憶當時情形,指出自己在美國哈佛大學公衛碩士及波士頓大學MBA唸書時,看到美國的連鎖醫療體系十分龐大。他思考,若是敏盛也能效法這樣的商業模式,就有機會串聯全台重要的醫療體系,提供患者更多的服務。
楊弘仁說服父親楊敏盛,在內部建立完整的治理架構,更一步步推動公司在台上市,近年更陸續入主躍獅連鎖藥局,終於將敏盛醫療打造成橫跨醫療、健康管理與生技研發的完整生態系。
「不能把接班當作理所當然!」楊弘仁也建議準備接班,或正在接班的二、三代,必須時時刻刻抱持謙遜、尊重長輩的心態。當遇到困難或挑戰時,得換位思考。「如果老闆不是你爸爸,很多事情更難推動,一定要有這種覺悟!」他強調。

📖遠見雜誌-家族企業交棒難在哪?大成、志聖、敏盛接班人分享心法
About
Information
Contact
桃園 桃園市桃園區經國路168號19樓 +886-3-346-9595
臺北 台北市大安區基隆路二段172-1號2樓 +886-2-66363996

Copyrights © 2026 盛弘醫藥股份有限公司 All Rights Reserved
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding ShareHope Medicine Co., Ltd.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.



